Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia.
Physostigmine was administered orally 1 mg q.i.d. for one month to 8 patients with a clinical diagnosis of Alzheimer's presenile dementia. The possible beneficial effects of the drug were evaluated by means of a neuropsychological battery administered to all patients before and after treatment. The performances obtained by demented patients on retest did not show any difference in comparison with performances obtained on the first neuropsychologic assessment. Some implications of these negative results are briefly discussed.
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D001143:Arousal / Q000187:drug effects; D003071:Cognition / Q000187:drug effects*; D003704:Dementia / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D008568:Memory / Q000187:drug effects*; D011939:Mental Recall / Q000187:drug effects*; D008875:Middle Aged; D010830:Physostigmine / Q000627:therapeutic use*; D011581:Psychological Tests
D010830:Physostigmine